Ad is loading...
NVAX
Price
$7.32
Change
+$0.10 (+1.39%)
Updated
Nov 15 closing price
107 days until earnings call
RXRX
Price
$6.17
Change
-$0.73 (-10.56%)
Updated
Nov 15 closing price
107 days until earnings call
Ad is loading...

NVAX vs RXRX

Header iconNVAX vs RXRX Comparison
Open Charts NVAX vs RXRXBanner chart's image
Novavax
Price$7.32
Change+$0.10 (+1.39%)
Volume$9.35M
CapitalizationN/A
Recursion Pharmaceuticals
Price$6.17
Change-$0.73 (-10.56%)
Volume$10.54M
CapitalizationN/A
NVAX vs RXRX Comparison Chart
Loading...
NVAX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
NVAX vs. RXRX commentary
Nov 17, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVAX is a Hold and RXRX is a StrongSell.

COMPARISON
Comparison
Nov 17, 2024
Stock price -- (NVAX: $7.32 vs. RXRX: $6.18)
Brand notoriety: NVAX: Notable vs. RXRX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVAX: 137% vs. RXRX: 207%
Market capitalization -- NVAX: $1.17B vs. RXRX: $1.77B
NVAX [@Biotechnology] is valued at $1.17B. RXRX’s [@Biotechnology] market capitalization is $1.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • NVAX’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, RXRX is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 3 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).

  • NVAX’s TA Score: 3 bullish, 5 bearish.
  • RXRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both NVAX and RXRX are a bad buy in the short-term.

Price Growth

NVAX (@Biotechnology) experienced а -17.85% price change this week, while RXRX (@Biotechnology) price change was -13.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

NVAX is expected to report earnings on Mar 04, 2025.

RXRX is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($1.77B) has a higher market cap than NVAX($1.17B). NVAX YTD gains are higher at: 52.500 vs. RXRX (-37.373). NVAX has higher annual earnings (EBITDA): -228.25M vs. RXRX (-348.35M). NVAX has more cash in the bank: 1.05B vs. RXRX (474M). RXRX has less debt than NVAX: RXRX (89.9M) vs NVAX (233M). NVAX has higher revenues than RXRX: NVAX (560M) vs RXRX (48.6M).
NVAXRXRXNVAX / RXRX
Capitalization1.17B1.77B66%
EBITDA-228.25M-348.35M66%
Gain YTD52.500-37.373-140%
P/E RatioN/AN/A-
Revenue560M48.6M1,152%
Total Cash1.05B474M222%
Total Debt233M89.9M259%
FUNDAMENTALS RATINGS
NVAX: Fundamental Ratings
NVAX
OUTLOOK RATING
1..100
56
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
PROFIT vs RISK RATING
1..100
97
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NVAXRXRX
RSI
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
N/A
Bullish Trend 7 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
88%
View a ticker or compare two or three
Ad is loading...
NVAX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FBSIX40.70-0.14
-0.34%
Franklin Mutual U.S. Mid Cap Value R6
PIXEX25.63-0.09
-0.35%
Principal Glb Emerging Markets R1
IGFFX36.56-0.20
-0.54%
American Funds Intl Gr and Inc F2
SNIEX21.55-0.12
-0.55%
BNY Mellon International Equity I
LEQCX11.43-0.09
-0.78%
LoCorr Dynamic Opportunity C

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with THRD. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then THRD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
+1.39%
THRD - NVAX
42%
Loosely correlated
-5.81%
ITOS - NVAX
39%
Loosely correlated
-2.72%
ADMA - NVAX
36%
Loosely correlated
-5.74%
RXRX - NVAX
33%
Loosely correlated
-10.64%
EDIT - NVAX
33%
Poorly correlated
-3.97%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with BEAM. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-10.64%
BEAM - RXRX
63%
Loosely correlated
-8.59%
CRSP - RXRX
56%
Loosely correlated
+0.85%
EXAI - RXRX
56%
Loosely correlated
-11.68%
PRME - RXRX
55%
Loosely correlated
-6.95%
NTLA - RXRX
54%
Loosely correlated
-7.61%
More